Aflac's Q4 2022 total revenues were $4.0 billion, compared to $5.4 billion in Q4 2021. Net earnings were $185 million, or $0.30 per diluted share, compared to $1.0 billion, or $1.57 per diluted share a year ago. Adjusted earnings were $806 million, compared to $850 million in Q4 2021. Adjusted earnings per diluted share increased 0.8% to $1.29 in the quarter.
Total revenues for Q4 2022 were $4.0 billion, a decrease from $5.4 billion in Q4 2021.
Net earnings for Q4 2022 were $185 million, or $0.30 per diluted share, a significant decrease from $1.0 billion, or $1.57 per diluted share a year ago, mainly due to foreign exchange-related net investment losses.
Adjusted earnings for Q4 2022 were $806 million, a decrease of 5.2% from $850 million in Q4 2021.
Aflac U.S. sales increased 17.4% in the quarter, while Aflac Japan sales increased 11.4%.
Aflac is encouraged by the sales increase of 11.4% in the fourth quarter in Japan and 17.4% in the U.S., reflecting a new cancer product launch and first sector product updates. The company is committed to prudent liquidity and capital management and continues to generate strong investment results while remaining in a defensive position as it monitors evolving economic conditions.